B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human
multiple myeloma (MM), has not been effectively targeted with therapeutic monoclonal …

Background IgG 4-related disease (IgG 4-RD) is a poorly understood, multiorgan, chronic
inflammatory disease characterized by tumefactive lesions, storiform fibrosis, obliterative …

Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the
field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues …

The antibody–drug conjugate field has made significant progress recently owing to careful
optimization of several parameters, including mAb specificity, drug potency, linker …

Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since
disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell …

Significant progress has been made in the past few years in the area of antibody drug
conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors. Early work in this …

Although TNFRSF 17 (also designated as B‐cell maturation antigen (BCMA)) is expressed
on tumour cells in B‐cell malignancies, it has not been found in serum. The present study …

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma
(MM), but expression is variable, and early reports of BCMA targeting chimeric antigen …